Literature DB >> 28416588

Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy.

Matteo Dal Ferro1, Davide Stolfo1, Alessandro Altinier1, Marta Gigli1, Martina Perrieri1, Federica Ramani1, Giulia Barbati1, Alberto Pivetta1, Francesca Brun1, Lorenzo Monserrat2, Mauro Giacca3, Luisa Mestroni4, Marco Merlo1, Gianfranco Sinagra1.   

Abstract

OBJECTIVE: To explore the genetic landscape of a well selected dilated cardiomyopathy (DCM) cohort, assessing the possible relation between different genotypes and left ventricular reverse remodelling (LVRR).
METHODS: A cohort of 152 patients with DCM from the Heart Muscle Disease Registry of Trieste has been studied by next-generation sequencing (NGS). Patients were grouped into different 'gene-clusters' with functionally homogeneous genetic backgrounds. LVRR was defined by left ventricular ejection fraction normalisation or increase ≥10% associated with normalisation in indexed left ventricular end-diastolic diameter or relative decrease ≥10% at 24 months follow-up.
RESULTS: A pathogenic disease-related gene variant was identified in 57% of patients: 28 (18%) TTN; 7 (5%) LMNA; 16 (11%) structural cytoskeleton Z-disk genes; 9 (6%) desmosomal genes; 18 (12%) motor sarcomeric genes and 9 (6%) other genes. Baseline clinical features were similar throughout the different genotypes. A significant relationship was found between gene cluster subgroups and LVRR, with a lower rate of LVRR in structural cytoskeleton Z-disk gene mutation carriers (1/16 patients, 6%, p<0.05 vs the other subgroups). Of note, structural cytoskeleton Z-disk gene rare variants were independently and inversely associated with LVRR when adjusted for clinical predictors of LVRR (OR 0.065; 95% CI 0.008 to 0.535, p=0.011).
CONCLUSIONS: NGS confirmed a high genetic diagnostic yield in DCM. A specific 'gene-clusters' classification based on functional similarities in different genes might be helpful in the clinical management of genetically determined DCM. In this study, structural cytoskeleton Z-disk gene rare variants were independently associated with a lower rate of LVRR at follow-up. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Clinical Genetics; Echocardiography; Idiopathic Dilated Cardiomyopathy.

Mesh:

Year:  2017        PMID: 28416588     DOI: 10.1136/heartjnl-2016-311017

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Identification and Functional Characterization of an ISL1 Mutation Predisposing to Dilated Cardiomyopathy.

Authors:  Ying-Jia Xu; Zhang-Sheng Wang; Chen-Xi Yang; Ruo-Min Di; Qi Qiao; Xiu-Mei Li; Jia-Ning Gu; Xiao-Juan Guo; Yi-Qing Yang
Journal:  J Cardiovasc Transl Res       Date:  2018-12-10       Impact factor: 4.132

2.  Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations.

Authors:  Fernando Domínguez; Sofía Cuenca; Zofia Bilińska; Rocío Toro; Eric Villard; Roberto Barriales-Villa; Juan Pablo Ochoa; Folkert Asselbergs; Arjan Sammani; Maria Franaszczyk; Mohammed Akhtar; Maria José Coronado-Albi; Diego Rangel-Sousa; Jose F Rodriguez-Palomares; Juan Jiménez-Jáimez; José Manuel Garcia-Pinilla; Tomás Ripoll-Vera; Maria Victoria Mogollón-Jiménez; Ana Fontalba-Romero; Dolores Garcia-Medina; Julian Palomino-Doza; David de Gonzalo-Calvo; Marcos Cicerchia; Joel Salazar-Mendiguchia; Clara Salas; Sabine Pankuweit; Thomas Morris Hey; Jens Mogensen; Paul J Barton; Philippe Charron; Perry Elliott; Pablo Garcia-Pavia
Journal:  J Am Coll Cardiol       Date:  2018-11-13       Impact factor: 24.094

Review 3.  Molecular insights into cardiomyopathies associated with desmin (DES) mutations.

Authors:  Andreas Brodehl; Anna Gaertner-Rommel; Hendrik Milting
Journal:  Biophys Rev       Date:  2018-06-20

Review 4.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

5.  The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.

Authors:  Ji-Hye Oh; Jae-Man Lee; Hee-Jung Lee; Jongmin Hwang; Cheol Hyun Lee; Yun-Kyeong Cho; Hyoung-Seob Park; Hyuck-Jun Yoon; Jin-Wook Chung; Hyungseop Kim; Chang-Wook Nam; Seongwook Han; Seung-Ho Hur; Jong-Chan Youn; In-Cheol Kim
Journal:  ESC Heart Fail       Date:  2022-04-28

Review 6.  Genetics of Dilated Cardiomyopathy: Clinical Implications.

Authors:  A Paldino; G De Angelis; M Merlo; M Gigli; M Dal Ferro; G M Severini; L Mestroni; G Sinagra
Journal:  Curr Cardiol Rep       Date:  2018-08-13       Impact factor: 2.931

7.  Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy.

Authors:  Marta Gigli; Marco Merlo; Sharon L Graw; Giulia Barbati; Teisha J Rowland; Dobromir B Slavov; Davide Stolfo; Mary E Haywood; Matteo Dal Ferro; Alessandro Altinier; Federica Ramani; Francesca Brun; Andrea Cocciolo; Ilaria Puggia; Gaetano Morea; William J McKenna; Francisco G La Rosa; Matthew R G Taylor; Gianfranco Sinagra; Luisa Mestroni
Journal:  J Am Coll Cardiol       Date:  2019-09-17       Impact factor: 24.094

8.  MAGGIC Risk Model Predicts Adverse Events and Left Ventricular Remodeling in Non-Ischemic Dilated Cardiomyopathy.

Authors:  Yang Dong; Dongfei Wang; Jialan Lv; Zhicheng Pan; Rui Xu; Jie Ding; Xiao Cui; Xudong Xie; Xiaogang Guo
Journal:  Int J Gen Med       Date:  2020-12-10

Review 9.  Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.

Authors:  Tomas Hnat; Josef Veselka; Jakub Honek
Journal:  ESC Heart Fail       Date:  2022-04-18

Review 10.  Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.

Authors:  Nicoletta Orphanou; Efstathios Papatheodorou; Aris Anastasakis
Journal:  Heart Fail Rev       Date:  2021-07-14       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.